What is ChromaCode?
ChromaCode is at the forefront of delivering advanced genomic solutions through its proprietary HDPCR multiplexing technology. The company's platform is designed to simplify complex data analysis, enabling faster and more cost-effective access to critical biomarkers. This technology is particularly impactful in oncology and broader genomics applications, offering customizable assays that support tumor profiling and disease monitoring. By providing a cost-effective alternative to conventional methods, ChromaCode empowers lab partners with enhanced molecular profiling capabilities, aiming to improve health outcomes through accessible and precise diagnostic tools.
How much funding has ChromaCode raised?
ChromaCode has raised a total of $50M across 2 funding rounds:
Series B
$12M
Series C
$38M
Series B (2017): $12M with participation from New Enterprise Associates and Domain Associates
Series C (2020): $38M led by Okapi Venture Capital, Domain Associates, Adjuvant Capital, Windham Ventures, California Institute of Technology, New Enterprise Associates, Moore Venture Partners, and Northpond Ventures
Key Investors in ChromaCode
New Enterprise Associates
New Enterprise Associates (NEA) is a prominent venture capital firm established in 1977, known for its focus on empowering entrepreneurs and building transformative businesses across various sectors.
Domain Associates
Domain Associates is a specialized investment advisory firm founded in 1985, with a deep focus on biotech investments, having supported numerous biopharmaceutical, device, and diagnostic companies through venture funding.
Okapi Venture Capital
Okapi Venture Capital has been actively seeding and scaling startups since 2005, concentrating on information technology and life sciences investments with a team possessing extensive experience in venture capital and technology leadership.
What's next for ChromaCode?
With the recent enterprise-level funding, ChromaCode is poised for accelerated growth and further innovation in the rapidly evolving field of genomic diagnostics. The company's strategic focus will likely involve scaling its operations, expanding its market reach, and enhancing its technological capabilities to meet the increasing demand for personalized medicine. Continued investment in research and development will be crucial for ChromaCode to maintain its competitive edge and solidify its position as a leader in providing actionable biomarker insights. The company's trajectory suggests a strong emphasis on strategic partnerships and market penetration to drive adoption of its HDPCR technology.
See full ChromaCode company page
